^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | Elyxyb (celecoxib) (COX2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer
Excerpt:
A mixed linear model was fit to the log-transformed tumor volume data. Sulindac, celecoxib, or aspirin treatment reduced the growth rates of MT PIK3CA tumors compared with vehicle-treated tumors (P < 0.0001; Fig. 2, A and B)....Only the PIK3CA-MT PDX exhibits growth inhibition upon celecoxib or aspirin treatment relative to vehicle (interaction test: linear P < 0.0001; quadratic P < 0.0001).
DOI:
10.1084/jem.20181936
